Shuttle Pharmaceuticals Holdings Inc(SHPH) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -30.81 | Insider Own | 0.11% | Shs Outstand | 4.8M | Perf Week | 6.11% |
| Market Cap | 0.02B | Forward P/E | - | EPS next Y | - | Insider Trans | -92.83% | Shs Float | 4.8M | Perf Month | 26.76% |
| Enterprise Value | 0.02B | PEG | - | EPS next Q | - | Inst Own | 0.54% | Short Float | 0.66% | Perf Quarter | 87.41% |
| Income | -0.01B | P/S | - | EPS this Y | - | Inst Trans | -1.6% | Short Ratio | 0.25 | Perf Half Y | -50.38% |
| Sales | 0.00B | P/B | 0.27 | EPS next 5Y | - | ROA | -72.47% | Short Interest | 0.03M | Perf YTD | -71.06% |
| Book/sh | 19.16 | P/C | 275.85 | EPS past 3/5Y | 61.57% 11.76% | ROE | -90.05% | 52W High | -88.27% ($44.40) | Perf Year | -83.72% |
| Cash/sh | 0.02 | P/FCF | - | Sales past 3/5Y | - | ROIC | -53.18% | 52W Low | 102.22% ($2.58) | Perf 3Y | -99.47% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 94.9% | Gross Margin | - | Volatility(W/M) | 15.8% 10.04% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.46 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.11 | EPS Q/Q | 90.59% | Profit Margin | - | RSI (14) | 59.6 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.11 | Sales Q/Q | - | SMA20 | 7.96% ($4.83) | Beta | 1.09 | Target Price | - |
| Payout | - | Debt/Eq | 0.01 | Earnings | - | SMA50 | 27.24% ($4.09) | Rel Volume | 0.08 | Prev Close | $5.05 |
| Employees | 2 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | - | SMA200 | -27.59% ($7.2) | Avg Volume(3M) | 0.13M | Price | $5.21 |
| IPO | 2022/8/31 | Option/Short | No/Yes | Trades | 234 | Volume | 10,352 | Change | 3.27% |
SHPHShuttle Pharmaceuticals Holdings Inc | NASD | Drug Manufacturers - Specialty & Generic Deep diveShuttle Pharmaceuticals is a US-based clinical-stage oncology biotech specializing in the development of radiation sensitizers, which enhance the effectiveness of radiation therapy. Its lead candidate, Ropidoxuridine, is currently in a Phase 2 clinical trial for glioblastoma, and the company is expanding its business scope through the acquisition of a prostate cancer diagnostic technology and an AI-powered drug discovery platform.
Over the past 1 year, on the lower side
88% below its 1-year high.
Traded less than usual. That is 8% of its average volume.
SHPH has weak earnings and a weak balance sheet
Review management risk carefully before investing
Tap to view numbers
Holding long would have lost money
Bought 3 years ago, your return today would be -99.5%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 0.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
DEXC Dimensional Emerging Markets ex China Core Equity ETF <0.01% 
EWX State Street SPDR S&P Emerging Markets Small Cap ETF <0.01% 
AVEE Avantis Emerging Markets Small Cap Equity ETF <0.01% 
DFAE Dimensional Emerging Core Equity Market ETF <0.01% 
DFAX Dimensional World ex U.S. Core Equity 2 ETF <0.01% It ranks #67 of 83 in the industry
Based on market cap of $25M.
RMTI#65 Rockwell Medical Inc $28M PER - 
CPHI#66 China Pharma Holdings Inc $27M PER - SHPH#67 Shuttle Pharmaceuticals Holdings Inc $25M PER - 
AYTU#68 Aytu BioPharma Inc $21M PER - 
TXMD#69 TherapeuticsMD Inc $21M PER - 
FAQ
What kind of company is SHPH?
SHPH belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of SHPH?
The market cap of SHPH is approximately $25M, ranking 5,149 within its sector.
What is the 52-week high and low for SHPH?
SHPH has recorded a 52-week high of $44.40 and a low of $2.58.
